0001193125-23-277535.txt : 20231115 0001193125-23-277535.hdr.sgml : 20231115 20231115072029 ACCESSION NUMBER: 0001193125-23-277535 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231115 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231115 DATE AS OF CHANGE: 20231115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Repare Therapeutics Inc. CENTRAL INDEX KEY: 0001808158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39335 FILM NUMBER: 231409031 BUSINESS ADDRESS: STREET 1: 7171 FREDERICK BANTING STREET 2: SUITE 270, BUILDING 2 CITY: SAINT-LAURENT STATE: A8 ZIP: H4S 1Z9 BUSINESS PHONE: (857) 412-7018 MAIL ADDRESS: STREET 1: 7171 FREDERICK BANTING STREET 2: SUITE 270, BUILDING 2 CITY: SAINT-LAURENT STATE: A8 ZIP: H4S 1Z9 8-K 1 d850546d8k.htm 8-K 8-K
00-0000000 false 0001808158 0001808158 2023-11-15 2023-11-15

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 15, 2023

 

 

Repare Therapeutics Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Québec   001-39335   Not applicable

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

7171 Frederick-Banting, Building 2, Suite 270

St-Laurent, Québec, Canada

   H4S 1Z9
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (857) 412-7018

Not Applicable

(Former Name or Former Address, if Changed Since Last Report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol

  

Name of each exchange

on which registered

Common shares, no par value   RPTX   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 7.01

Regulation FD Disclosure.

Repare Therapeutics Inc. (the “Company”) will host a conference call and webcast beginning at 8:00 a.m. Eastern Time on Wednesday, November 15, 2023, at which the Company will present on the progress of its RP-1664 and RP-3467 programs. The Company’s RP-1664 product candidate is a selective, oral PLK4 inhibitor that is synthetic lethal with TRIM37 amplification or overexpression in solid tumors. The Company’s RP-3467 product candidate is an inhibitor of DNA polymerase theta (“Polq”). Polq is a synthetic lethal target associated with homologous recombination deficiency tumors, including those with BRCA1/2 mutations or other genomic alterations. The Company is posting a copy of the presentation to be used on the conference call and webcast to the “Investors & Media” section of its website at https://ir.reparerx.com/investor-relations.

The information contained in Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

The Company’s website and any information contained on the Company’s website are not incorporated into this Current Report on Form 8-K.

 

Item 8.01

Other Events.

On November 15, 2023, the Company issued a press release announcing highlights of its conference call and webcast, including the proposed timing of the Company’s Phase 1 clinical trials of RP-1664 and RP-3467. A copy of the release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibit.

(d) Exhibits

 

Exhibit

No.

   

Description

99.1    Press release dated November 15, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

REPARE THERAPEUTICS INC.
By:  

/s/ Lloyd M. Segal

  Lloyd M. Segal
  President and Chief Executive Officer

Dated: November 15, 2023

 EX-99.1 2 d850546dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polq Inhibitor

RP-1664 demonstrated potent and selective inhibition of PLK4 and synthetic lethality in TRIM37-high tumor cells in preclinical studies

RP-3467 demonstrated complete, sustained regressions preclinically in combination with PARPi, and compelling anti-tumor activity in combination with radioligand therapy (RLT) and chemotherapy

Company expects to initiate clinical trials of RP-1664 in 1H 2024 and RP-3467 in 2H 2024

Repare to host conference call and webcast today at 8:00 a.m. ET

CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE) — November 15, 2023 — Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today disclosed polo-like kinase 4 (PLK4) as the target of its RP-1664 development program and reported comprehensive preclinical data for both RP-1664 and the Company’s Polq inhibitor, RP-3467.

RP-1664 is a potential first-in-class, selective, oral PLK4 inhibitor that is synthetic lethal with TRIM37 amplification or overexpression in solid tumors. Tumors rely on PLK4 for survival in the presence of high levels of TRIM37. Preclinical studies demonstrate RP-1664 drives potent synthetic lethality in TRIM37-high tumor models, both in vitro and in vivo. Elevated TRIM37 is a feature found across a range of solid tumors and in nearly all high-grade neuroblastomas.

RP-3467 is a potential best-in-class inhibitor of DNA polymerase theta, or Polq. Polq is a synthetic lethal target associated with homologous recombination deficiency (HRD) tumors, including those with BRCA1/2 mutations or other genomic alterations. Data suggest that RP-3467 works synergistically with therapies that result in double stranded DNA breaks, such as PARP inhibition, radioligand therapy and multiple chemotherapies and antibody-drug conjugates (ADCs). Additionally, initial data suggest that Polq inhibition may interfere with mechanisms central to the development of PARPi resistance.

“We are excited to announce the initial clinical approach for RP-1664 based on highly compelling preclinical data supporting its potential for treating TRIM37-high tumors,” said Lloyd M. Segal, President and CEO of Repare. “We are also pleased to share preclinical data from our RP-3467 program supporting its significant potential across multiple high-value therapeutic opportunities. These programs represent our third and fourth internally developed clinical candidates and provide further confirmation of Repare’s powerful discovery platform. We look forward to advancing both RP-1664 and RP-3467 into Phase 1 clinical trials in 2024.”

RP-1664 Highlights

 

  •  

RP-1664 is a highly potent, selective and bioavailable PLK4 inhibitor that is synthetic lethal with TRIM37 gain of function.

  •  

RP-1664 demonstrated robust and dose-dependent monotherapy activity in multiple TRIM37-high preclinical models across a variety of tumor types, including breast cancer, non-small cell lung cancer (NSCLC) and neuroblastoma.

 

  •  

The Company plans to initiate a Phase 1 dose escalation study of RP-1664 in adult and adolescent patients with TRIM37-high solid tumors in the first half of 2024.

RP-3467 Data Highlights

 

  •  

RP-3467 is a highly potent and selective inhibitor of the Polq helicase domain.

 

  •  

RP-3467 demonstrates synergy with PARP inhibitor activity, resulting in durable, complete tumor regressions in multiple preclinical models.

 

  •  

Preclinical studies also show combination potential with multiple other modalities, including RLT, chemotherapy and ADCs.

 

  •  

The Company plans to initiate a Phase 1 dosing finding clinical trial of RP-3467 in the second half of 2024.

“Preclinical data for RP-1664 demonstrate early and promising activity in TRIM37-high tumors, including breast cancer, NSCLC and neuroblastoma,” said Michael Zinda, Ph.D., EVP, Chief Scientific Officer of Repare. “The durable, complete regressions observed in the preclinical RP-3467 and PARPi combination studies are also extremely exciting and demonstrate the broad combination potential of our potent and selective Polq helicase inhibitor. Repare plans to investigate RP-3467 with a focus on its potential as a combination partner across agents that induce double stranded DNA breaks, including RLT, ADCs, and a range of chemotherapies.”

Conference Call and Webcast

Repare will host a conference call and webcast today, November 15, 2023, at 8:00 a.m. ET. To access the call, please dial (877) 870-4263 (U.S. and Canada) or (412) 317-0790 (international) at least 10 minutes prior to the start time and ask to be joined to the Repare Therapeutics call. A live webcast will be available in the Investor section of the Company’s website at https://ir.reparerx.com/events-and-presentations/events. A webcast replay will also be archived for at least 30 days.

About Repare Therapeutics’ SNIPRx® Platform

Repare’s SNIPRx® platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Company’s therapies based on the genetic profile of their tumors. Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx® screening, in order to selectively target those tumors in patients most likely to achieve clinical benefit from resulting product candidates.

About Repare Therapeutics Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500 or RG6526), a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche; RP-3467, a preclinical Polq inhibitor program; RP-1664, a preclinical PLK4 inhibitor; as well as several additional, undisclosed preclinical programs. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are “forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the design, objectives, initiation, timing, progress and results of the Company’s current and future preclinical studies and clinical trials, including specifically the clinical development of RP-1664 and RP-3467 programs; the tolerability, efficacy and clinical progress of RP-1664 and RP-3467; the potential of RP-1664 as a first-in-class oral PLK4 inhibitor and RP-3467 as a best-in-class Polq inhibitor; and the benefits and ability to discover further targets and clinical candidates from the Company’s discovery platform. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including the COVID-19 pandemic, the conflict in Ukraine and the conflict between Israel and Hamas, rising inflation, and uncertain credit and financial markets on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (“SEC”) and the Québec Autorité des Marchés Financiers (“AMF”) on February 28, 2023, and its other documents subsequently filed with or furnished to the SEC and AMF including the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 filed with the SEC on November 9, 2023. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit reparerx.com and follow Repare on Twitter at @RepareRx and on LinkedIn at https://www.linkedin.com/company/repare-therapeutics/.

Repare Contact:

Steve Forte

Executive Vice-President and Chief Financial Officer

Repare Therapeutics Inc.

investor@reparerx.com

Investors:

Matthew DeYoung

Argot Partners

repare@argotpartners.com

Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

EX-101.SCH 3 rptx-20231115.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rptx-20231115_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 1 Entity Address City Or Town Entity Address City Or Town Entity Address State Or Province Entity Address State Or Province Entity Address Country Entity Address Country Entity Address Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key EX-101.PRE 5 rptx-20231115_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g850546g1115051751048.jpg GRAPHIC begin 644 g850546g1115051751048.jpg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htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 15, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 15, 2023
Entity Registrant Name Repare Therapeutics Inc.
Entity Incorporation State Country Code A8
Entity File Number 001-39335
Entity Tax Identification Number 00-0000000
Entity Address Address Line 1 7171 Frederick-Banting, Building 2, Suite 270
Entity Address City Or Town St-Laurent
Entity Address State Or Province QC
Entity Address Country CA
Entity Address Postal Zip Code H4S 1Z9
City Area Code 857
Local Phone Number 412-7018
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common shares, no par value
Trading Symbol RPTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001808158
XML 8 d850546d8k_htm.xml IDEA: XBRL DOCUMENT 0001808158 2023-11-15 2023-11-15 00-0000000 false 0001808158 8-K 2023-11-15 Repare Therapeutics Inc. A8 001-39335 7171 Frederick-Banting, Building 2, Suite 270 St-Laurent QC CA H4S 1Z9 857 412-7018 false false false false Common shares, no par value RPTX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 000001 - Document - Document and Entity Information Sheet http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d850546d8k.htm rptx-20231115.xsd rptx-20231115_lab.xml rptx-20231115_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d850546d8k.htm": { "nsprefix": "rptx", "nsuri": "http://www.reparerx.com/20231115", "dts": { "inline": { "local": [ "d850546d8k.htm" ] }, "schema": { "local": [ "rptx-20231115.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "rptx-20231115_lab.xml" ] }, "presentationLink": { "local": [ "rptx-20231115_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "000001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-11-15_to_2023-11-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d850546d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-11-15_to_2023-11-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d850546d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "terseLabel": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "terseLabel": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "terseLabel": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Country", "terseLabel": "Entity Address Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.reparerx.com//20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-23-277535-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-277535-xbrl.zip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end